Linvencorvir

SKU: orb1685819

Description

Linvencorvir is a small molecule therapeutic candidate that modifies the hepatitis B virus core protein. It is used in research to investigate novel mechanisms for suppressing HBV replication in both cellular and animal models of chronic infection.

Research Area

Cell Biology, Infectious Disease & Virology

Key Properties

• CAS Number: 1808248-05-6
• MW: 598.69
• Purity: >99.99% (May vary between batches)
• Formula: C₂₉H₃₅FN₆O₅S
• SMILES: C(OCC)(=O)C=1[C@@H](NC(=NC1CN2C[C@@]3(N(CC2)C(=O)N(CC(C(O)=O)(C)C)C3)[H])C4=NC=CS4)C5=C(C)C(F)=CC=C5
• Target: HBV,Antibiotic,Apoptosis
• Solubility: DMSO:128.8 mg/mL (215.14 mM)

Bioactivity

• Target IC50:
  HepG2.2.15 cells:6 nM (EC50)
• In Vivo:
  Linvencorvir (RO7049389) (600/1000 mg; oral; Caucasian and Asian, male and female) followed by 100 μg intravenous [13 C]RO7049389. The model performance in predicting the pharmacokinetic profiles of RO7049389 aligned with clinical observations in Caucasians and was also successfully applied to Asians. Accordingly, the drug disposition pathways for RO7049389 were postulated with newly characterized estimates of the fractions: biliary excretion by P-glycoprotein (~41%), direct glucuronidation via uridine 5'-diphosphoglucuronosyltransferase 1A3 (~11%), hexose conjugation (~6%), oxidation by CYP3A4 (~28%) and other oxidation reactions (~9%). These results support the ongoing clinical development program for RO7049389 and highlight the broader value of PBPK and MB analyses in drug development.
  Read more...

Storage & Handling

• Storage: -20°C
• Expiration Date: 12 months from date of receipt.
• Disclaimer: For research use only

Alternative Names

Linvencorvir, HBV, Antibiotic, RG 7907, RG7907, RG-7907

Compound Identifiers

PubChem CID

118354396